The Fine Line between Success and Failure in Scleroderma Lung Fibrosis Trials

Christopher J Ryerson^{1

2}, Christopher P Denton³

Affiliations

¹ 1 Centre for Heart Lung Innovation.
² 2 Department of Medicine St. Paul's Hospital and University of British Columbia Vancouver, Canada and.
³ 3 Centre for Rheumatology Royal Free Hospital and University College London London, United Kingdom.

Editorial

Christopher J Ryerson et al. Am J Respir Crit Care Med. 2018.

. 2018 Mar 1;197(5):553-554.

doi: 10.1164/rccm.201711-2268ED.

Christopher J Ryerson^{1

2}, Christopher P Denton³

¹ 1 Centre for Heart Lung Innovation.
² 2 Department of Medicine St. Paul's Hospital and University of British Columbia Vancouver, Canada and.
³ 3 Centre for Rheumatology Royal Free Hospital and University College London London, United Kingdom.

No abstract available

Comment on

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D. Kafaja S, et al. Am J Respir Crit Care Med. 2018 Mar 1;197(5):644-652. doi: 10.1164/rccm.201709-1845OC. Epub 2017 Nov 3. Am J Respir Crit Care Med. 2018. PMID: 29099620 Free PMC article.